Abstract
The research of rare and devastating orphan diseases such as Idiopathic Pulmonary Fibrosis (IPF) has been limited by the rarity of the disease itself. The prognosis is poor – the prevalence of IPF is only ∼4-times the incidence of the condition, limiting the recruitment of patients to trials and studies of the underlying biology of the disease. However, global biobanking efforts can dramatically alter the future of IPF research.
Here we describe the largest meta-analysis of IPF, with 8,492 patients and 1,355,819 population controls from 13 biobanks around the globe. Finally, we combine the meta-analysis with the largest available meta-analysis of IPF so far, reaching 11,160 patients and 1,364,410 population controls in analysis.
We identify seven novel genome-wide significant loci, only one of which would have been identified if the analysis had been limited to European ancestry individuals. We observe notable pleiotropy across IPF susceptibility and severe COVID-19 infection, beyond what is known to date. We also note a significant unexplained sex-heterogeneity effect at the strongest IPF locus MUC5B.
Competing Interest Statement
M.J.D. is a founder of Maze Therapeutics. A.S. and B.L.Y are full time employees of Genentech with stock and stock options in Roche. R.G.J. has received research funding from Astra Zeneca, Biogen, Galecto, GlaxoSmithKline, RedX, and Pliant; consulting fees from Bristol Myers Squibb, Daewoong, Veracyte, Resolution Therapeutics, RedX, and Pliant; payment for lectures, presentations, speakers bureaus, manuscript writing or educational events from Chiesi, Roche, PatientMPower, and AstraZeneca; payment for Participation on a Data Safety Monitoring Board or Advisory Board from Boehringer Ingelheim, Galapagos, and Vicore, had an Leadership or fiduciary role in other board, society, committee or advocacy group (unpaid) in NuMedii and Action for Pulmonary Fibrosis; Trustee for Action for Pulmonary Fibrosis. L.V.W. has received research funding from GSK and Orion Pharma, and consultancy for Galapagos. J.T.K and M.J.D are members of the Pfizer Finland FinnGen Advisory Board. Other co-authors report no conflicts of interest.
Funding Statement
This work was supported by the Doctoral Programme in Population Health, University of Helsinki [to JJP]; and The Finnish Medical Foundation [to JJP]; RJA is an Action for Pulmonary Fibrosis Mike Bray Research Fellow, NHLBI [to JO]; Wellcome Trust to [BGG]; Spanish Ministry of Science and Innovation and Instituto de Salud Carlos III, co-financed by by the European Regional Development Fund (ERDF) from the European Union (EU) to [CF]; Cabildo Insular de Tenerife to [CF]; NIH [to IN], Medical Research Council - Project Grant [to RGJ]; NIHR Research Professorship [to RGJ]; GSK/British Lung Foundation Chair in Respiratory Research (C17-1) [to LVW]; Research Foundation of the Pulmonary Diseases HES [to RK]; Jalmari and Rauha Ahokas Foundation [to RK]; the Research Foundation of North Finland, Oulu, Finland and a state subsidy of Oulu University Hospital [to RK]; HUS State Research Funding [to MM]. The work of the contributing biobanks for GBMI was supported by numerous grants from governmental and charitable bodies, see Supplementary Material. The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Please refer to Supplementary Material for information regarding individual studies involved in the Global Biobank Meta-analysis Initiative. Regarding the latest published IPF meta-analysis, this research was conducted using previously published work with appropriate ethics approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Full summary statistics and code are available per request.
